ARPINO, GRAZIA
ARPINO, GRAZIA
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition.
2004 Arpino, Grazia; Weiss, H; Wakeling, Ae; Osborne, K; Schiff, R.
GMO-Gestione Malattie Oncologiche in Regione Campania.
2011 Arpino, Grazia; Cammarota, Simona; DE ANGELIS, Carmine; Pizzi, Claudia; Perone, Vincenzo; Tommasielli, Giuseppina; Arpino, Giovanni; Novellino, Ettore; DE PLACIDO, Sabino
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
2005 Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, R. M.
Predictive value of apoptosis, proliferation, and HER-2 for anthracycline chemotherapy in patients with locally advanced breast cancer
2003 Arpino, Grazia; D. R., Ciocca; H., Weiss; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S., Mohsin
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
2004 Arpino, Grazia; Stephanie J., Green; D., Craig Allred; Dannika, Lew; Silvana, Martino; C., Kent Osborne; Richard M., Elledge
Cancer mortality trends between 1988 and 2009 in the metropolitan area of Naples and Caserta, Southern Italy: Results from a joinpoint regression analysis.
2013 Crispo, A; Barba, M; Malvezzi, M; Arpino, Grazia; Grimaldi, M; Rosso, T; Esposito, E; Sergi, D; Ciliberto, G; Giordano, A; Montella, M.
HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study
2002 Arpino, Grazia; S., Green; Dc, Allred; P., Ravdin; D., Lew; S., Martino; Ck, Osborne; R., Elledge
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies
2002 DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco
Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes
2005 Arpino, Grazia; H., Weiss; R., Elledge
Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts.
2006 M. F., Rimawi; H. L., Weiss; Arpino, Grazia; G. S., Morris; R. D., Soliz; R. M., Ward; T. M., Gilmer; C. K., Osborne; R., Schiff
Estrogen receptor-positive, progesterone receptor-negative breast cancer: correlation with growth factor receptor expression and tamoxifen resistance.
2004 Arpino, Grazia; Weiss, H; Lee, A; Schiff, R; Osborne, Ck; Elledge, Rm
Capitolo 4 - Terapia Medica
2011 G., Tortora; F., Ciardiello; Arpino, Grazia; A. R., Bianco
Triple-negative breast cancers: Biomarkers and outcomes
2010 Malorni, L.; Shetty, P. B.; Hilsenbeck, S. G.; Rimawi, M. F.; Elledge, R. M.; De Angelis, C.; Osborne, C. K.; DE PLACIDO, Sabino; Arpino, Grazia
Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) on core needle biopsy (CNB) — Clinical significance
2003 Arpino, Grazia; C., Allred; S., Mohsin; H., Weiss; D., Conrow; R., Elledge
Idoxifene vs. Tamoxifen: A Randomized Comparison in Postmenopausal Patients with Metastatic Breast Cancer
2002 Arpino, Grazia; Nair Krishnan, M; Doval Dinesh, C; V. J., Bardou; G., Clark; R., Elledge
The hormone receptor status of a contralateral breast cancer is independent of the first primary in patients not receiving adjuvant systemic therapy.
2003 Arpino, Grazia; H., Weiss; S., Hilsenbeck; K., Osborne
Imaging tests in staging and surveillance of early breast cancer in Italy. changes in routine clinical practice and costs implications
2010 Cammarota, Simona; Menditto, Enrica; Citarella, Anna; Putignano, D.; Riegler, S.; Arpino, Grazia
Progesterone receptor (PgR) status provides additional information to estrogen receptor (ER) status for predicting clinical outcomes of primary breast cancer patients treated with adjuvant endocrine therapy.
2002 V. J., Bardou; Arpino, Grazia; R. M., Elledge; G. M., Clark
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
2005 DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, C; Ciardiello, F; Tortora, Giampaolo; D'Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, Rossella; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino
Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN).
2012 M. F., Rimawi; C. J., Poole; J. M., Ferrero; J. R., De la Haba Rodriguez; L., Mitchell; C. H., Pelizon; Arpino, Grazia
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition. | 4.1 Articoli in Atti di convegno | 2004 | Arpino, Grazia; Weiss, H; Wakeling, Ae; Osborne, K; Schiff, R. | |
| GMO-Gestione Malattie Oncologiche in Regione Campania. | 2.1 Contributo in volume (Capitolo o Saggio) | 2011 | Arpino, Grazia; Cammarota, Simona; DE ANGELIS, Carmine; Pizzi, Claudia; Perone, Vincenzo; Tommasielli, Giuseppina; Arpino, Giovanni; Novellino, Ettore; DE PLACIDO, Sabino | |
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, R. M. | |
| Predictive value of apoptosis, proliferation, and HER-2 for anthracycline chemotherapy in patients with locally advanced breast cancer | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; D. R., Ciocca; H., Weiss; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S., Mohsin | |
| HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. | 1.1 Articolo in rivista | 2004 | Arpino, Grazia; Stephanie J., Green; D., Craig Allred; Dannika, Lew; Silvana, Martino; C., Kent Osborne; Richard M., Elledge | |
| Cancer mortality trends between 1988 and 2009 in the metropolitan area of Naples and Caserta, Southern Italy: Results from a joinpoint regression analysis. | 1.1 Articolo in rivista | 2013 | Crispo, A; Barba, M; Malvezzi, M; Arpino, Grazia; Grimaldi, M; Rosso, T; Esposito, E; Sergi, D; Ciliberto, G; Giordano, A; Montella, M. | |
| HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study | 4.1 Articoli in Atti di convegno | 2002 | Arpino, Grazia; S., Green; Dc, Allred; P., Ravdin; D., Lew; S., Martino; Ck, Osborne; R., Elledge | |
| HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies | 1.5 Abstract in rivista | 2002 | DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco | |
| Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes | 4.1 Articoli in Atti di convegno | 2005 | Arpino, Grazia; H., Weiss; R., Elledge | |
| Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts. | 4.1 Articoli in Atti di convegno | 2006 | M. F., Rimawi; H. L., Weiss; Arpino, Grazia; G. S., Morris; R. D., Soliz; R. M., Ward; T. M., Gilmer; C. K., Osborne; R., Schiff | |
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: correlation with growth factor receptor expression and tamoxifen resistance. | 4.1 Articoli in Atti di convegno | 2004 | Arpino, Grazia; Weiss, H; Lee, A; Schiff, R; Osborne, Ck; Elledge, Rm | |
| Capitolo 4 - Terapia Medica | 2.1 Contributo in volume (Capitolo o Saggio) | 2011 | G., Tortora; F., Ciardiello; Arpino, Grazia; A. R., Bianco | |
| Triple-negative breast cancers: Biomarkers and outcomes | 4.1 Articoli in Atti di convegno | 2010 | Malorni, L.; Shetty, P. B.; Hilsenbeck, S. G.; Rimawi, M. F.; Elledge, R. M.; De Angelis, C.; Osborne, C. K.; DE PLACIDO, Sabino; Arpino, Grazia | |
| Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) on core needle biopsy (CNB) — Clinical significance | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; C., Allred; S., Mohsin; H., Weiss; D., Conrow; R., Elledge | |
| Idoxifene vs. Tamoxifen: A Randomized Comparison in Postmenopausal Patients with Metastatic Breast Cancer | 4.1 Articoli in Atti di convegno | 2002 | Arpino, Grazia; Nair Krishnan, M; Doval Dinesh, C; V. J., Bardou; G., Clark; R., Elledge | |
| The hormone receptor status of a contralateral breast cancer is independent of the first primary in patients not receiving adjuvant systemic therapy. | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; H., Weiss; S., Hilsenbeck; K., Osborne | |
| Imaging tests in staging and surveillance of early breast cancer in Italy. changes in routine clinical practice and costs implications | 1.5 Abstract in rivista | 2010 | Cammarota, Simona; Menditto, Enrica; Citarella, Anna; Putignano, D.; Riegler, S.; Arpino, Grazia | |
| Progesterone receptor (PgR) status provides additional information to estrogen receptor (ER) status for predicting clinical outcomes of primary breast cancer patients treated with adjuvant endocrine therapy. | 4.1 Articoli in Atti di convegno | 2002 | V. J., Bardou; Arpino, Grazia; R. M., Elledge; G. M., Clark | |
| A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. | 1.1 Articolo in rivista | 2005 | DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, C; Ciardiello, F; Tortora, Giampaolo; D'Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, Rossella; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino | |
| Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN). | 4.1 Articoli in Atti di convegno | 2012 | M. F., Rimawi; C. J., Poole; J. M., Ferrero; J. R., De la Haba Rodriguez; L., Mitchell; C. H., Pelizon; Arpino, Grazia |